With the wishes and expectations from well-known endocrinologists in China, who were quoted as saying that "The new long-acting hypoglycemic drug, polyethylene glycol loxenatide injection, will provide a new strategy for the treatment of diabetes" and "One injection a week, Fulaimei will bring good news to diabetic patients", Hansoh Pharma's long-acting hypoglycemic drug Fulaimei (polyethylene glycol loxenatide injection) was launched in Beijing on July 25.
Fulaimei is the world's first PEGylated GLP-1 weekly preparation independently developed by Hansoh Pharma to improve glycemic control in patients with type 2 diabetes. Professor Guo Lixin, Chairman-elect of the Chinese Diabetes Society of the Chinese Medical Association, remarked that Fulaimei has definite hypoglycemic effect and good safety, is more convenient due to once-a-week dosing, and is expected to provide a new, highly efficacious, safe and convenient strategy of blood sugar control for doctors and patients after its launch.
The demand of diabetic patients is the key to meeting treatment targets. According to Professor Shan Zhongyan, Vice Chairman of the Chinese Society of Endocrinology of the Chinese Medical Association, the research and development of Fulaimei adopts the “patient needs centered” approach, and its use alone or combined use with metformin to control blood sugar can significantly reduce the level of HbA1c, increase the rate of blood sugar compliance, produce only mild gastrointestinal adverse reactions, hypoglycemia incidence and antibody incidence, and also bring multiple benefits such as improved β-cell function and body weight loss; one injection a week can greatly reduce the number of injections, resulting in easy injection operation and better patient compliance.
It is noteworthy that as shown in the report titled Reflections on the Mechanism of Cardiovascular Benefits of GLP-1 Receptor Agonist , the metabolic dynamics analysis, together with the results of more than ten multi-center randomized double-blind controlled clinical studies on cardiovascular endpoints, indicates that the double exposure to GLP-1 in time and dose is a common rule of whether drug interventions in various studies end up with positive results, the summary of which provides an outlook on possible cardiovascular benefits of GLP-1 drugs. As a GLP-1 weekly preparation, Fulaimei has dual advantages in exposure time and exposure dose.
During the meeting, the “Senmei China Diabetes Research Fund Project” jointly sponsored by Chinese Journal of Diabetes Mellitus and China International Medical Foundation was kicked off at the same time. Based on donation and support from Jiangsu Hansoh Pharmaceutical Group Co., Ltd., the project is intended to support medical clinical research with "GLP-1 receptor agonist weekly formulation" as the core therapeutic method, and is also expected to provide new ideas and new ways for the treatment of type 2 diabetes in China, thus helping improve the quality of life of patients and promote the development of health in China.
In the final discussion and summary part, the participating experts agreed that Fulaimei would bring innovative treatment options and more comprehensive clinical benefits to diabetes treatment after its launch, and expressed their expectation of Hansoh Pharma’s continued efforts to promote the launch of SGLT-2, DPP-4, GLP-1 oral preparations and other new anti-hyperglycemic drugs, so as to provide a multi-faceted management scheme for the vast number of diabetic patients in China.
